Amrutanjan Health Care Ltd
Healthcare | Small Cap
Amrutanjan Health Care Ltd. demonstrates robust financial health, characterized by exceptional profitability, impressive growth, and a virtually debt-free status. The company's reliance on its own funds for financing assets provides a strong foundation of long-term stability, making it highly resilient. It has consistently expanded its revenues and profits, indicating strong market demand and operational success. Key strengths include outstanding profitability margins and efficient inventory management, which contribute to its healthy cash generation. However, the company shows more moderate performance in how efficiently it uses its total capital to generate sales. While fundamentally very strong, direct shareholder return metrics like earnings and book value per share are average. The future outlook is positive, driven by strong growth momentum and a pristine balance sheet. The main area of observation will be how effectively its large capital base is utilized to drive top-line sales and enhance shareholder value metrics over time.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsHighly Overvalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio5.40
- Profitability Ratio10.00
- Efficiency Ratio6.67
- Coverage Ratio9.20
- Solvency Ratio10.00
- Liquidity Ratio9.20
- Peer Assessment
- Management AssessmentStrong
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursBearish
- 4 HoursStrong Bearish
- 1 DayBearish
- 1 WeekNeutral
- 1 MonthBearish
Amrutanjan Health Care Ltd. demonstrates robust financial health, characterized by exceptional profitability, impressive growth, and a virtually debt-free status. The company's reliance on its own funds for financing assets provides a strong foundation of long-term stability, making it highly resilient. It has consistently expanded its revenues and profits, indicating strong market demand and operational success. Key strengths include outstanding profitability margins and efficient inventory management, which contribute to its healthy cash generation. However, the company shows more moderate performance in how efficiently it uses its total capital to generate sales. While fundamentally very strong, direct shareholder return metrics like earnings and book value per share are average. The future outlook is positive, driven by strong growth momentum and a pristine balance sheet. The main area of observation will be how effectively its large capital base is utilized to drive top-line sales and enhance shareholder value metrics over time.
Overall Valuation Score
P/E RATIO (TTM)
27.23
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
77.37
P/B RATIO
14.66
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
8.91
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
5.23
EV/EBITDA RATIO
42.43
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹545.45 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company has demonstrated exceptionally strong and broad-based growth. It has consistently expanded its revenues, operating profits, and net income at a very high rate. This comprehensive growth is also reflected in rising earnings for shareholders and an expanding asset base. This performance indicates a highly successful business strategy, strong market demand for its healthcare products, and a very positive trajectory for future expansion and continued profitability.
| Growth Ratios | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 34.65 | -3.68 | 2.29 | 17.91 | 12.03 |
| Operating Profit Growth Rate | 38.46 | -5.56 | 29.41 | 9.09 | 29.17 |
| Earnings Per Share (EPS) Growth | 4.52 | 22.77 | 19.72 | 38.24 | |
| Asset Growth Rate | -21.02 | 0 | -3.23 | 3.33 | 12.9 |
| Net Income Growth Rate | 0 | 0 | 20 | 25 | 40 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics from a direct shareholder perspective are average. While capital expenditure demonstrates a prudent and controlled approach to investment, key value metrics like earnings per share and the underlying book value per share are at moderate levels. Similarly, cash earnings and dividends paid per share are not particularly high. This suggests that while the company is stable and profitable, the direct financial returns and value accruing to each share are standard rather than exceptional.
| Financial Ratios | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 3.33 | 3.27 | 4.2 | 5 | 6.93 |
| Cash Earnings Per Share (Cash EPS) | 4.33 | 4.67 | 5.33 | 6 | 8 |
| Book Value Per Share | 25.67 | 27.33 | 29.67 | 31.67 | 36.33 |
| Dividend Per Share (DPS) | 1.49 | 1.49 | 1.62 | 1.73 | 1.9 |
| Capital Expenditures (CapEx) | 4 | 0.9 | 0.8 | 5.8 | 1.3 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is exceptional across all measures. It achieves strong margins from its initial sales down to its final net profit. It is also highly effective at generating returns on the capital invested by both lenders and shareholders, as well as on its total assets. This comprehensive, high-level profitability demonstrates superior operational efficiency, strong pricing power, and effective cost control, placing the company in a top-tier position in its industry.
| Profitability Ratios | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|
| Gross Profit Margin | 11.03 | 9.92 | 13.43 | 13.29 | 15.82 |
| Return on Capital Employed (ROCE) | 16 | 18 | 23 | 26 | 31 |
| Return on Equity (ROE) | 12.99 | 12.2 | 13.48 | 15.79 | 19.27 |
| Return on Assets (ROA) | 14.52 | 13.71 | 18.33 | 19.35 | 22.14 |
| Operating Margin | 13.24 | 12.98 | 16.42 | 15.19 | 17.51 |
| Net Margin | 7.35 | 7.63 | 8.96 | 9.49 | 11.86 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's operational efficiency is a mix of strengths and areas of standard performance. It excels at managing inventory, selling products very quickly. However, its effectiveness in using its fixed assets and overall capital to generate sales is more moderate. The time it takes to collect payments from customers is also at an average level. This indicates that while certain aspects of its operations, like inventory control, are top-tier, other areas reflect a more typical performance for the industry.
| Efficiency Ratios | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 4.12 | 4.37 | 4.96 | 6.58 | 6.1 |
| Inventory Turnover Ratio | 10.31 | 10 | 12.24 | 15.81 | 16.84 |
| Receivables Turnover Ratio | 9.21 | 5.71 | 5.04 | 6.01 | 6.41 |
| Days Sales in Inventory Ratio | 35.4 | 36.5 | 29.82 | 23.09 | 21.67 |
| Receivable Days | 39.63 | 63.92 | 72.42 | 60.73 | 56.94 |
| Capital Turnover Ratio | 1.6 | 1.6 | 1.51 | 1.66 | 1.62 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to meet its financial commitments is outstanding. It generates more than enough profit to cover its interest payments, a position amplified by its very low debt levels. Furthermore, its earnings provide a strong and sustainable cushion for its dividend payments to shareholders. This indicates a very low-risk financial profile, with profits comfortably supporting both its minor obligations and its shareholder return policies, showcasing excellent financial prudence.
| Coverage Ratios | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 6.33 | 8.5 | 10.5 | 25 | N/A |
| Equity Dividend Coverage Ratio | 2.22 | 2.33 | 2.63 | 2.94 | 3.7 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's long-term financial stability is exceptional. It operates with virtually no debt, financing its assets almost entirely with equity. This near-zero leverage strategy means it faces minimal financial risk from interest rate fluctuations or economic pressures, as it is not dependent on external lenders for its survival. This self-reliant financial structure is a cornerstone of its strength, providing a very strong foundation for sustainable, long-term operations and growth.
| Solvency Ratios | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|
| Debt Ratio | 0.09 | 0 | 0 | 0 | 0 |
| Debt to Equity Ratio | 0.1 | 0 | 0 | 0 | 0 |
| Equity Ratio | 0.91 | 1 | 1 | 1 | 1 |
| Debt To Asset Ratio | 0.06 | 0 | 0 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company exhibits an exceptionally strong ability to meet its short-term financial obligations. It possesses a very high level of liquid assets, including cash, relative to its immediate debts, indicating a very low risk of short-term financial distress. This robust position points to excellent financial stability and the capacity to handle unexpected expenses without difficulty. While its ability to generate cash from core operations to cover these debts is average, its overall cash and near-cash holdings provide a substantial safety net, reflecting a very secure short-term financial standing.
| Liquidity Ratios | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|
| Current Ratio | 1.59 | 1.64 | 2.68 | 3.05 | 3.24 |
| Quick Ratio | 1.25 | 1.4 | 2.4 | 2.75 | 2.95 |
| Cash Ratio | 0.39 | 0.35 | 1.14 | 1.33 | 1.53 |
| Operating Cash Flow Ratio | 0.1 | 0.21 | 0.55 | 0.63 | 0.67 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 5 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 6 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 9 | Hester Biosciences Ltd | 6.54 | 31.74 | Neutral | 87.00 | 61.24 | 57.00 |
| 10 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 17 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 18 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
Management effectiveness is assessed as strong. This is primarily driven by outstanding financial performance, characterized by accelerating profit growth that significantly outpaces sales growth, indicating strong operational efficiency and margin expansion. The company demonstrates prudent financial management with a historically low-debt balance sheet and a consistent record of sharing profits through dividends. Capital efficiency metrics like ROCE and ROE are robust and stable. While operational and financial indicators are strong, a significant projected decrease in promoter shareholding presents a notable governance concern. The negative stock performance, despite strong fundamentals, appears linked to a high valuation.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Strong Profit Growth | TTM: 37% | Outstanding |
| Healthy Capital Returns | ROCE: 22.58% | Strong | |
| Prudent Debt Management | Historically Low Borrowings | Excellent | |
| Consistent Dividend Payout | Avg >25% (2012-16) | Stable | |
| CONS | Projected Promoter Holding Decrease | -4.07% drop (2024-25) | Weak |
| Negative Stock Price Performance | 1-Year CAGR: -22% | Poor |
Financial Performance & Growth
The company exhibits excellent financial performance, driven by exceptionally strong and accelerating profit growth. While sales growth has been stable and healthy, profit growth has surged, particularly over the last three years and in the trailing twelve months (TTM). The TTM profit growth of 37% against a sales growth of 12% indicates significant margin expansion and high operational leverage, reflecting effective cost management. This trend showcases the management's ability to translate top-line revenue into disproportionately higher bottom-line profits.
| Metric | 10 Years | 5 Years | 3 Years | TTM |
|---|---|---|---|---|
| Compounded Sales Growth (%) | 10% | 12% | 11% | 12% |
| Compounded Profit Growth (%) | 13% | 15% | 27% | 37% |
Capital Efficiency & Returns
Management has demonstrated good capital efficiency, consistently generating healthy returns. The current Return on Capital Employed (ROCE) stands at a strong 22.58%. The Return on Equity (ROE) has been stable and is improving in the shorter term, indicating that shareholder funds are being used productively to generate profits. The historical data shows a consistent ability to maintain double-digit returns over various timeframes, signifying a sustainable and efficient business model.
| Metric | 10-Year Avg | 5-Year Avg | 3-Year Avg | Last Year |
|---|---|---|---|---|
| Return on Equity (%) | 15% | 15% | 17% | 20% |
Financial Health & Prudence
The company's financial health is excellent, reflecting a prudent and conservative approach to financial management. Historically, the company has maintained very low levels of debt, as evidenced by the significant reduction in borrowings over the years. In March 2016, borrowings were a minimal ₹2 Cr. Furthermore, management has a long-standing policy of rewarding shareholders, maintaining a consistent and healthy dividend payout ratio. This combination of a strong, debt-light balance sheet and shareholder-friendly actions underscores financial prudence.
| Metric | 2012–2014 (Avg) | 2015–2016 (Avg) |
|---|---|---|
| Borrowings (₹ Cr) | 15 | 2 |
| Metric | 2012–2014 (Avg) | 2015–2016 (Avg) |
|---|---|---|
| Dividend Payout (%) | 42% | 31% |
Shareholding & Ownership Structure
The ownership structure presents a mixed picture. On the positive side, promoter holding has been stable for years at a substantial level of around 50%. Additionally, there is a trend of increasing interest from institutional investors (DIIs and FIIs). However, a significant governance concern arises from the projected decrease in promoter holding from over 50% to 46.52% by March 2025. This planned reduction is a material change that introduces uncertainty.
| Shareholding (%) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 (Proj.) |
|---|---|---|---|---|
| Promoters | 50.02% | 50.03% | 50.59% | 46.52% |
| FIIs | 1.43% | 0.68% | 1.38% | 2.30% |
| DIIs | 6.14% | 7.18% | 7.29% | 11.41% |
The overall risk profile is moderate. While the company's operational and financial health is strong with low fundamental risk, there are significant governance and market-related risks. The most prominent risk is the projected substantial decrease in promoter shareholding, which raises questions about future control and strategy. This governance signal is a material concern. This is compounded by an extremely high valuation, as indicated by a P/E ratio of 79.2, which has contributed to negative stock price performance despite strong business growth. This combination of governance uncertainty and high valuation creates a notable risk profile.
Governance & Ownership Risk
A significant forward-looking governance red flag is the projected reduction in promoter holding from 50.59% (Mar 2024) to 46.52% (Mar 2025). A nearly 4.1% stake sale by the core ownership group is a material event that can signal a shift in promoter confidence or strategy, creating uncertainty for other shareholders. While historical promoter holding was stable, this planned change in the ownership structure constitutes a significant governance risk.
Valuation & Market Risk
The company's P/E ratio of 79.2 is extremely high, indicating the stock is priced richly relative to its earnings. This high valuation has likely contributed to the poor recent stock performance, with a 1-year stock price CAGR of -22%. The disconnect between strong business performance and negative stock performance highlights a significant valuation risk for investors.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10548.63Bearish
- SMA 20544.03Bearish
- SMA 50551.55Bearish
- EMA 10547.87Bearish
- EMA 20547.25Bearish
- EMA 50549.68Bearish
- DEMA 10549.30Bearish
- DEMA 20546.66Bearish
- DEMA 50546.05Bearish
- TEMA 10549.66Bearish
- TEMA 20548.98Bearish
- TEMA 50544.41Bearish
- MACD-0.04Bullish
- ADX16.96Weak Trend
- IndicatorValueSignal
- RSI44.06Neutral
- CCI17.79Neutral
- ROC 90.31Bullish
- ROC 141.59Bullish
- ROC 25-1.67Bearish
- Stoch K70.51Neutral
- Stoch D79.55Neutral
- IndicatorValueSignal
- BB Upper554.89Neutral
- BB Middle544.03Neutral
- BB Lower533.16Neutral
- ATR5.62High Volatility
- IndicatorValueSignal
- MFI46.03Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10544.82Bearish
- SMA 20547.31Bearish
- SMA 50552.26Bearish
- EMA 10546.86Bearish
- EMA 20548.12Bearish
- EMA 50551.51Bearish
- DEMA 10546.74Bearish
- DEMA 20545.01Bearish
- DEMA 50547.96Bearish
- TEMA 10548.48Bearish
- TEMA 20544.77Bearish
- TEMA 50545.69Bearish
- MACD-2.09Bullish
- ADX13.57Weak Trend
- IndicatorValueSignal
- RSI42.45Neutral
- CCI-28.83Neutral
- ROC 91.22Bullish
- ROC 14-1.15Bearish
- ROC 25-3.03Bearish
- Stoch K64.18Neutral
- Stoch D66.64Neutral
- IndicatorValueSignal
- BB Upper561.25Neutral
- BB Middle547.31Neutral
- BB Lower533.38Neutral
- ATR7.38Low Volatility
- IndicatorValueSignal
- MFI23.28Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
- IndicatorValueSignal
- SMA 10546.69Bearish
- SMA 20553.43Bearish
- SMA 50554.43Bearish
- EMA 10547.63Bearish
- EMA 20550.42Bearish
- EMA 50552.88Bearish
- DEMA 10544.44Bearish
- DEMA 20546.54Bearish
- DEMA 50552.93Bearish
- TEMA 10544.18Bearish
- TEMA 20544.42Bearish
- TEMA 50N/AN/A
- MACD-3.14Bearish
- ADX15.72Weak Trend
- IndicatorValueSignal
- RSI43.34Neutral
- CCI-60.78Neutral
- ROC 9-2.53Bearish
- ROC 14-4.08Bearish
- ROC 25-0.58Bearish
- Stoch K41.35Neutral
- Stoch D34.84Neutral
- IndicatorValueSignal
- BB Upper571.47Neutral
- BB Middle553.43Neutral
- BB Lower535.39Neutral
- ATR10.82High Volatility
- IndicatorValueSignal
- MFI16.85Oversold
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10552.80Bearish
- SMA 20554.08Bearish
- SMA 50555.50Bearish
- SMA 100565.08Bearish
- SMA 200631.83Bearish
- EMA 10549.19Bearish
- EMA 20552.23Bearish
- EMA 50556.55Bearish
- EMA 100574.20Bearish
- EMA 200608.37Bearish
- DEMA 10544.74Bullish
- DEMA 20548.97Bearish
- DEMA 50545.16Bullish
- DEMA 100534.38Bullish
- DEMA 200555.25Bearish
- TEMA 10542.50Bullish
- TEMA 20545.81Bearish
- TEMA 50554.71Bearish
- TEMA 100533.73Bullish
- TEMA 200527.25Bullish
- MACD-2.95Bearish
- ADX11.90Weak Trend
- IndicatorValueSignal
- RSI45.65Neutral
- CCI-79.59Neutral
- ROC 14-2.57Bearish
- ROC 25-4.95Bearish
- Stoch K23.04Neutral
- Stoch D19.74Oversold
- IndicatorValueSignal
- BB Upper571.16Neutral
- BB Middle554.08Neutral
- BB Lower536.99Neutral
- ATR17.25High Volatility
- IndicatorValueSignal
- MFI35.72Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20563.03Bearish
- SMA 50642.52Bearish
- EMA 20572.84Bearish
- EMA 50617.93Bearish
- DEMA 20536.59Bullish
- DEMA 50567.55Bearish
- TEMA 20538.17Bullish
- TEMA 50536.26Bullish
- MACD-24.89Bullish
- ADX23.58Weak Trend
- IndicatorValueSignal
- RSI42.10Neutral
- CCI-85.06Neutral
- ROC 14-0.40Bearish
- ROC 25-18.46Bearish
- Stoch K59.08Neutral
- Stoch D52.02Neutral
- IndicatorValueSignal
- BB Upper632.83Neutral
- BB Middle563.03Neutral
- BB Lower493.23Neutral
- ATR38.95Low Volatility
- IndicatorValueSignal
- MFI50.70Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6578.76Bearish
- SMA 12638.62Bearish
- SMA 24680.27Bearish
- EMA 6581.81Bearish
- EMA 12616.59Bearish
- EMA 24646.42Bearish
- DEMA 6544.61Bullish
- DEMA 12570.08Bearish
- DEMA 24616.63Bearish
- TEMA 6539.63Bullish
- TEMA 12543.75Bullish
- TEMA 24577.74Bearish
- MACD-0.76Bearish
- ADX20.13Weak Trend
- IndicatorValueSignal
- RSI46.42Neutral
- CCI-126.83Oversold
- ROC 25-20.04Bearish
- ROC 50-29.69Bearish
- Stoch K35.98Neutral
- Stoch D46.18Neutral
- IndicatorValueSignal
- BB Upper799.66Neutral
- BB Middle659.32Neutral
- BB Lower518.98Neutral
- ATR96.44Low Volatility
- IndicatorValueSignal
- MFI60.75Neutral